• Recruiting

NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide


NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide


dara

NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide


The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lenalidomide) with giving daratumumab as maintenance therapy, and they will look at which drug gives participants a better health-related quality of life during treatment. The researchers will measure participants' quality of life using various questionnaires. This study will help researchers find out whether this different approach of giving daratumumab as maintenance therapy is better, the same as, or worse than the usual approach.


Sponsor

Memorial Sloan Kettering Cancer Center


Collaborator

Janssen Scientific Affairs, LLC

 

ClinicalTrials.gov Identifier: NCT04497961

Official Title: Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

First Posted : August 4, 2020

Click here for details on ClinicalTrials.gov

 

Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute

Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

 

Drug: Lenalidomide

Drug: Daratumumab

Behavioral: Questionnaires

 

Locations

United States, New Jersey

United States, New York


Posts Archive